Hologic Inc Stock Price, News & Analysis

Hologic, Inc. (Nasdaq: HOLX) has received CE marking for its new Panther Fusion EBV and BKV Quant Assays, expanding its transplant pathogen monitoring capabilities. These in vitro nucleic acid amplification tests enable accurate quantitation of Epstein-Barr Virus and BK Virus in transplant patients, crucial for diagnosis and treatment management. The Panther Fusion system processes whole blood and plasma samples, which are vital for monitoring viral levels. This marks a significant addition as the first quantitative assays from Hologic's Liege facility.

Hologic, Inc. (NASDAQ: HOLX) recently announced FDA approval for its Aptima CMV Quant assay, the first quantitative test for monitoring cytomegalovirus (CMV) in solid organ and stem cell transplant patients. This innovative test enhances patient outcomes by providing standardized clinical information and is fully automated on the Panther® system. With existing capabilities for viral load testing in HIV-1 and Hepatitis, Hologic aims to improve the management of transplant patients susceptible to infections. Future assays for BK Virus and Epstein-Barr Virus are in development.

Hologic, Inc. (NASDAQ: HOLX) will be participating in two key investor conferences. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 8:00 a.m. Pacific Time, while the William Blair 42nd Annual Growth Stock Conference is set for June 7 at 2:00 p.m. Central Time. Both presentations will be available via live webcast on Hologic's investor website, accessible for 30 days post-event. Hologic focuses on advancing women’s health through innovative medical technologies.

Hologic reported Q2 fiscal 2022 revenue of $1.436 billion, a 6.6% decline compared to the previous year, primarily due to lower COVID-19 assay sales. However, this figure exceeded the company's guidance of $1.25 to $1.3 billion. GAAP diluted EPS was $1.80, down 24.4% year-over-year, with non-GAAP diluted EPS at $2.07. Despite declines in various segments, the company raised its full-year revenue and EPS guidance, reflecting strong cash flow from operations of $1.062 billion and a robust balance sheet.

Hologic announces that the American Society of Clinical Oncology (ASCO) has updated its guidelines to include Breast Cancer Index™ (BCI) as the only genomic test for determining extended endocrine therapy in early-stage, HR+ breast cancer patients. This guideline aims to help healthcare providers make informed treatment decisions after five years of primary therapy. BCI is recognized for its ability to predict which patients may benefit from continued treatment, mitigating unnecessary side effects associated with extended therapy.

Hologic, Inc. (Nasdaq: HOLX) has announced the release of its second-quarter fiscal 2022 financial results, scheduled for April 27, after market close. A conference call will follow at 4:30 p.m. Eastern Time for discussion of the results. Participants can join by dialing specific numbers or click here to join. A replay will be available post-call until May 27, 2022.

Hologic, Inc. (NASDAQ: HOLX) has launched a new Innovation Center in Aix-en-Provence, France, marking a significant expansion of its commitment to women's health. This facility, which serves as the new French headquarters, will focus on ultrasound, interventional, and surgical solutions in breast health care. Following the acquisition of SuperSonic Imagine in 2019, Hologic aims to enhance access to innovative healthcare technologies in the EMEA region. The investment reflects Hologic's mission to improve the health of 3.9 billion women worldwide.